The approval of 633 abbreviated new drug applications so far in fiscal 2017 has put the FDA on pace to exceed last year's 651 approvals. The agency has said it still needs to address the speed of reviews for complex generics and find ways to reduce the number of review cycles.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.